The discovery of AQP4-IgG in 2005 represented a major breakthrough, allowing NMOSD to be distinguished from MS with high specificity and transforming diagnostic and therapeutic approaches (7, 17). This evidence concerns the gene AQP4 and myeloid sarcoma.